{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:50:23Z","timestamp":1700873423056},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>During the last few decades, the increased use of various types of antibiotics in the general population caused a significant change in regional <jats:italic>Helicobacter pylori<\/jats:italic> (<jats:italic>H. pylori)<\/jats:italic> antibiotic resistance. Our aim is to study the changes in <jats:italic>H. pylori<\/jats:italic> resistance in patients who had undergone an esophagogastroduodenoscopy (EGD) and susceptibility testing and found positive for <jats:italic>H. pylori.<\/jats:italic> The study was conducted in a university affiliated hospital between 2013\u20132020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study was performed on all consecutive patients who had undergone an EGD and tested positive for <jats:italic>H. pylori<\/jats:italic> at the Kaplan Medical Center, Israel. The study period was divided into two sub-periods: 2013\u20132016 and 2017\u20132020. Data on age, sex, comorbidities, previous treatments, and antimicrobial susceptibility testing for six antimicrobial agents were compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The resistance rates of <jats:italic>H. pylori<\/jats:italic> to clarithromycin and dual resistance to clarithromycin and metronidazole were found significantly higher during the late period. Multivariable analysis showed that the later period, older age, and diabetes mellitus were independent predictors for antimicrobial resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study has shown that there is an increasing resistance of <jats:italic>H. pylori<\/jats:italic> to clarithromycin and metronidazole while its susceptibility is unaffected with time to other antibiotics. More recent cross-sectional studies with larger samples are warranted in order to evaluate the changes in the resistance patterns of <jats:italic>H. pylori<\/jats:italic> to various antibiotics with time.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01500-0","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:02:35Z","timestamp":1700820155000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The epidemiology of Helicobacter pylori resistance in a university affiliated hospital: a comparison between two time periods\u2014a cross-sectional design"],"prefix":"10.1186","volume":"28","author":[{"given":"Haim","family":"Shmuely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yekaterina","family":"Shvartsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Berdinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehud","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"1500_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/CMR.00011-10","volume":"23","author":"LE Wroblewski","year":"2010","unstructured":"Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713\u20139.","journal-title":"Clin Microbiol Rev"},{"key":"1500_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1017\/S0950268811002081","volume":"140","author":"K Muhsen","year":"2012","unstructured":"Muhsen K, Cohen D, Spungin-Bialik A, Shohat T. Seroprevalence, correlates and trends of Helicobacter pylori infection in the Israeli population. Epidemiol Infect. 2012;140:1207\u201314.","journal-title":"Epidemiol Infect"},{"key":"1500_CR3","first-page":"466","volume":"18","author":"R Lavy","year":"2016","unstructured":"Lavy R, Hershkovitz Y, Keinan-Boker L, Halevy A. Incidence and trends of gastrointestinal malignancies in Jewish and Arab populations in Israel over 32 years. Isr Med Assoc J. 2016;18:466\u20139.","journal-title":"Isr Med Assoc J"},{"key":"1500_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:51\u201369.","journal-title":"Gastroenterology"},{"key":"1500_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","volume":"12","author":"DY Graham","year":"2014","unstructured":"Graham DY, Lee Y, Wu M. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12:177-86.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1500_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.diagmicrobio.2005.12.003","volume":"55","author":"J Yahav","year":"2006","unstructured":"Yahav J, Shmuely H, Niv Y, Samra Z. In vitro activity of levofloxacin against Helicobacter pylori isolates from patients after treatment failure. Diagn Microbiol Infect Dis. 2006;55:81\u20133.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1500_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3109\/00365521003663688","volume":"45","author":"N Zevit","year":"2010","unstructured":"Zevit N, Levy I, Shmuely H, Samra Z, Yahav J. Antibiotic resistance of Helicobacter pylori in Israeli children. Scand J Gastroenterol. 2010;45:550\u20135.","journal-title":"Scand J Gastroenterol"},{"key":"1500_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12493","volume":"23","author":"I Lopo","year":"2018","unstructured":"Lopo I, Lib\u00e2nio D, Pita I, Dinis-Ribeiro M, Pimental-Nunes P. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis. Helicobacter. 2018;23: e12493.","journal-title":"Helicobacter"},{"key":"1500_CR9","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, 2021. http:\/\/www.eucast.org."},{"key":"1500_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s100960100611","volume":"20","author":"Y Glupczynski","year":"2001","unstructured":"Glupczynski Y, M\u00e9graud F, Lopez-Brea M, Andersen LP. European multicenter survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 2001;20:820\u20133.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1500_CR11","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","volume":"70","author":"F Megraud","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815\u201322.","journal-title":"Gut"},{"key":"1500_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.17235\/reed.2019.6198\/2019","volume":"111","author":"J Valle Mu\u00f1oz","year":"2019","unstructured":"Valle Mu\u00f1oz J, Mu\u00f1oz G\u00f3mez P, Sierra Bernal C, de Andr\u00e9s E, G\u00f3mez Hernando C, G\u00f3mez RR. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Rev Esp Enferm Dig. 2019;111:655\u201361.","journal-title":"Rev Esp Enferm Dig"},{"key":"1500_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34\u201342.","journal-title":"Gut"},{"key":"1500_CR14","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1128\/JCM.02642-10","volume":"49","author":"VY Miendje Deyi","year":"2011","unstructured":"Miendje Deyi VY, Bontems P, Vanderpas J, de Koster E, Ntounda R, Van den Borre C, Cadranel S, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Micro. 2011;49:2200\u20139.","journal-title":"J Clin Micro"},{"key":"1500_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ijantimicag.2009.05.008","volume":"34","author":"JA Karlowsky","year":"2009","unstructured":"Karlowsky JA, Lagac\u00e9-Wiens Philippe RS, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents. 2009;34:375\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"1500_CR16","doi-asserted-by":"publisher","first-page":"vi3","DOI":"10.1093\/jac\/dkr190","volume":"66","author":"N Adriaenssens","year":"2011","unstructured":"Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997\u20132009). J Antimicrob Chemother. 2011;66:vi3-12.","journal-title":"J Antimicrob Chemother"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155:1372\u201382.","journal-title":"Gastroenterology"},{"key":"1500_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/157339905774574275","volume":"1","author":"V Ojetti","year":"2005","unstructured":"Ojetti V, Migneco A, Silveri N, Ghirlanda G, Gasbarrini G, Gasbarrini A. The role of H. pylori infection in diabetes. Curr Diabetes Rev. 2005;1:343\u20137.","journal-title":"Curr Diabetes Rev"},{"key":"1500_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.diagmicrobio.2010.03.010","volume":"67","author":"L Boyanova","year":"2010","unstructured":"Boyanova L, Nikolov R, Gergova G, Evstatiev I, Lazarova E, Kamburov V, et al. Two-decade trends in primary Helicobacter pylori resistance to antibiotics in Bulgaria. Diagn Microbiol Infect Dis. 2010;67:319\u201326.","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01500-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01500-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01500-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:06:58Z","timestamp":1700820418000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01500-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01500-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kaplan Medical Center\u2019s institutional review board approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"538"}}